PMID: 12772502May 30, 2003Paper

Cellular uptake and intracellular fate of antisense oligonucleotides

Current Opinion in Molecular Therapeutics
Alain R ThierryB Lebleu

Abstract

Antisense oligonucleotides and short interfering RNAs are routinely used for gene function analysis and are being developed for clinical applications. The mechanism underlying internalization of free oligonucleotides into cells is poorly understood and inefficient in most cases. Antisense oligonucleotide delivery into ex vivo cells is routinely improved by the addition of cationic lipids. New chemical modifications and vectors allowing improved cellular delivery in vivo are being developed.

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Charles M RudinMark J Ratain
Journal of Controlled Release : Official Journal of the Controlled Release Society
Yoshinobu UenoMamoru Nakanishi
Chembiochem : a European Journal of Chemical Biology
Fanny MarlinCarine Giovannangeli
© 2022 Meta ULC. All rights reserved